In senescent cells, FOXO4 binds to p53, preventing apoptosis
[15] [16] Measurement of blood level is important in assessing prognosis, higher levels predicting a worse prognosis
Putting myself in Pfizers shoes, the real kicker, beyond the potential for a better product profile, is how the potency and dosing of Metseras molecules lower API requirements and impact COGs
Major trends in the forecast period include rapid expansion of glp-1 receptor agonist adoption, rising use of semaglutide for obesity beyond diabetes, growing preference for once-weekly injectable therapies, increasing acceptance of oral glp-1 formulations, higher demand for long-term metabolic disease management
These clinical decisions correspond to exacerbation or attenuation of the TBI-induced reduction in GI microbiome diversity over time [109]